The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for ...

In contrast, Eli Lilly (NYSE: LLY) and Hims & Hers Health (NYSE: HIMS) both jumped on today's news. They rose 2.7% and 7%, ...

The president’s clash with some of the nation’s biggest law firms appears to be far from over, potentially splintering the ...

People who develop type 2 diabetes face an increased risk of some of the most lethal cancers, including liver and pancreatic ...

A United States Senator has disclosed a series of stock trades, some raising questions about possible insider information use ...

When we last looked at Lantheus in May, its stock was trading just under $80 a share. As a reminder, Lantheus Holdings, Inc.

With a mix of power and quick hands, Jett Humphreys guided the AHS Falcons to a 10-2 win over the Lebanon Pioneers.

After Trump threatened 25% tariffs on pharma imports, J&J became the latest pharma company to announce investments in the U.S.

BEIJING (AP) — U.S. Sen. Steve Daines, a strong supporter of President Donald Trump, has met a senior Chinese diplomat in ...

Discover why Eli Lilly and Company is set for a strong 2024 with a robust pipeline, solid financials, and strategic growth ...

Johnson & Johnson says it will invest more than $55 billion within the United States over the next four years, including four ...

Clinical hold lifted for late stage cadisegliatin program for diabetes CATT1 Phase 3 trial in patients with type 1 diabetes (T1D) expected to resume Q2 2025 Strengthens commercial leadership with appo ...